Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ripretinib + Binimetinib in GIST
NCT05080621Phase 2Withdrawn
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Nov 2021
- Primary completion
- Nov 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 2, open-label trial of ripretinib and binimetinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Deciphera Pharmaceuticals. Primary endpoints: Incidence of adverse events at 12 months, Maximum Tolerated Dose and Recommended Phase 2 Dose at 12 months and 1 more. Planned start Nov 2021; status: withdrawn.
02
Drugs
ripretinibbinimetinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT05080621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05080621.